Launch excellence for diabetes medicines
08 August 2012
Download Type: Adobe PDF
Sarah Rickwood and Carolyn Gauntlett from the European Thought Leadership Group
IMS Health discuss the market for non-insulin diabetes treatments.
They discuss the market for first DPP-IV inhibitors and another major new class, the SGLT-2s.